Status:
COMPLETED
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
Lead Sponsor:
Amgen
Conditions:
Breast Cancer
Metastases
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.
Eligibility Criteria
Inclusion
- Inclusion Criteria: - Histologically or cytologically confirmed breast adenocarcinoma
- At least one bone metastasis
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00091832
Start Date
September 1 2004
End Date
October 1 2006
Last Update
January 28 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.